| An actin network dispatches ciliary GPCRs into extracellular vesicles to modulate signaling AR Nager, JS Goldstein, V Herranz-Pérez, D Portran, F Ye, ... Cell 168 (1), 252-263. e14, 2017 | 349 | 2017 |
| BBSome trains remove activated GPCRs from cilia by enabling passage through the transition zone F Ye, AR Nager, MV Nachury Journal of Cell Biology 217 (5), 1847-1868, 2018 | 235 | 2018 |
| The intraflagellar transport protein IFT27 promotes BBSome exit from cilia through the GTPase ARL6/BBS3 GM Liew, F Ye, AR Nager, JP Murphy, JS Lee, M Aguiar, DK Breslow, ... Developmental cell 31 (3), 265-278, 2014 | 206 | 2014 |
| The oral-facial-digital syndrome gene C2CD3 encodes a positive regulator of centriole elongation C Thauvin-Robinet, JS Lee, E Lopez, V Herranz-Pérez, T Shida, B Franco, ... Nature genetics 46 (8), 905-911, 2014 | 145 | 2014 |
| Single molecule imaging reveals a major role for diffusion in the exploration of ciliary space by signaling receptors F Ye, DK Breslow, EF Koslover, AJ Spakowitz, WJ Nelson, MV Nachury Elife 2, e00654, 2013 | 139 | 2013 |
| HURP regulates chromosome congression by modulating kinesin Kif18A function F Ye, L Tan, Q Yang, Y Xia, LW Deng, M Murata-Hori, YC Liou Current biology 21 (18), 1584-1591, 2011 | 57 | 2011 |
| NuSAP modulates the dynamics of kinetochore microtubules by attenuating MCAK depolymerisation activity C Li, Y Zhang, Q Yang, F Ye, SY Sun, ES Chen, YC Liou Scientific reports 6 (1), 18773, 2016 | 42 | 2016 |
| Chemical structure-guided design of dynapyrazoles, cell-permeable dynein inhibitors with a unique mode of action JB Steinman, CC Santarossa, RM Miller, LS Yu, AS Serpinskaya, ... Elife 6, e25174, 2017 | 30 | 2017 |
| PLK1 interacts and phosphorylates Axin that is essential for proper centrosome formation K Ruan, F Ye, C Li, YC Liou, SC Lin, SY Lin PloS one 7 (11), e49184, 2012 | 24 | 2012 |
| Cytoplasmic dynein antagonists with improved potency and isoform selectivity SK See, S Hoogendoorn, AH Chung, F Ye, JB Steinman, T Sakata-Kato, ... ACS chemical biology 11 (1), 53-60, 2016 | 20 | 2016 |
| An engineered IL-21 with half-life extension enhances anti-tumor immunity as a monotherapy or in combination with PD-1 or TIGIT blockade H Liu, R Wang, D An, H Liu, F Ye, B Li, J Zhang, P Liu, X Zhang, S Yao, ... International Immunopharmacology 101, 108307, 2021 | 11 | 2021 |
| Dose-dependent mutual regulation between Wip1 and p53 following UVC irradiation Y Xia, Q Yang, X Gong, F Ye, YC Liou The international journal of biochemistry & cell biology 43 (4), 535-544, 2011 | 11 | 2011 |
| Synergism Between IL21 and Anti-PD-1 Combination Therapy is Underpinned by the Coordinated Reprogramming of the Immune Cellular Network in the Tumor Microenvironment S Wu, H Huang, R Sun, DS Gao, F Ye, J Huang, E Li, A Ni, KGK Lu, ... Cancer research communications 3 (8), 1460-1472, 2023 | 1 | 2023 |
| Cytokine fusion proteins, and their pharmaceutical compositions and therapeutic applications Z Zhong, F Ye, M Siegel, J Huang US Patent 11,692,020, 2023 | 1 | 2023 |
| 1104 A safe and highly potent PD-1-IL-2 fusion (AWT020) that decouples the efficacy and toxicity of IL-2 therapy F Ye, Z Huang, L Cheng, J Huang, S Chen, M Hua, D Huang, E Li, J Jiang, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | 1 | 2022 |
| Cytokine fusion proteins and uses thereof Z Zhong, F Ye, M Siegel, J Huang, E Liao, E Li US Patent App. 17/253,481, 2021 | 1 | 2021 |
| Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications F Ye, E Liao, E Li, M Siegel, J Huang, Z Zhong US Patent 11,897,930, 2024 | | 2024 |
| Cytokine fusion proteins, and their pharmaceutical compositions and therapeutic applications Z Zhong, F Ye, M Siegel, J Huang US Patent App. 18/346,250, 2023 | | 2023 |
| Abstract LB029: AWT030: a first-in-class bi-functional IL-21 fusion protein selectively activates tumor infiltrated CD8 T cells and suppresses Treg cells F Ye, J Huang, S Chen, E Li, J Jiang, H Lin, M Hua, D Huang, Z Huang, ... Cancer Research 83 (8_Supplement), LB029-LB029, 2023 | | 2023 |
| A HIGHLY POTENT ANTI-LAG-3-IL-2C THAT SELECTIVELY TARGETS TUMOR-SPECIFIC CD8 (+) T CELLS Z Huang, J Huang, F Ye, S Chen, D Huang, M Hua, E Li, J Jiang, H Lin, ... Journal for ImmunoTherapy of Cancer 10, A1130-A1130, 2022 | | 2022 |
Elena KosloverDept of Physics, UCSDBestätigte E-Mail-Adresse bei physics.ucsd.edu
